Combined regulation of FXR with other targets, such as soluble epoxide hydrolase (sEH), has shown enhanced therapeutic effects in NASH, particularly in terms of anti-inflammatory and anti-fibrotic outcomes (80). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.